CD19 drugs for Diffuse Large B-Cell Lymphoma
2 tracked CD19 drugs in the Diffuse Large B-Cell Lymphoma race. The class explanation lives on the CD19 page; the full indication pipeline across every mechanism is on the Diffuse Large B-Cell Lymphoma page.
1 approved / phase 41 preclinical / unstaged
Head-to-head evidence: Tafasitamab vs Zugocabtagene geleucel